Mundipharma has appointed Dr Alberto Martinez as its new president and chief executive officer, succeeding Antony Mattessich, who leaves the network after 12 years of service to pursue his career in the US.
Dr Martinez’ career has seen him gain expertise in the healthcare and pharmaceutical fields, more specifically in the strategic, financial and operational capacity.
His new role will see him take responsibility for strengthening Mundipharma’s network in Europe and focus on its alliances.
Additionally, research and development, global manufacturing, supply chain and IT functions will fall under Dr Martinez’s new remit.
He said: “I feel honoured and privileged to be given the opportunity to lead the Mundipharma organisations in Europe in the next chapter of our evolution and success. I am committed to ensure that we remain ambitious and agile so we continue to bring valuable and innovative medicines to patients and healthcare providers as a successful, diversified and forward-thinking organisation.”
Dr Martinez originally joined the Mundipharma network in 2003 and has held roles of increasing responsibility over the past 14 years.
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.